The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count

Journal of Surgical Oncology

Volumn 93, Issue 6, 2006, Pages 446-455

  Romani, Antonello A ^a   Borghetti, Angelo F ^a   Del Rio, Paolo ^b   Sianesi, Mario ^b   Soliani, Paolo ^b,c  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^c Aziendit Ospedaliero Universitztria di Parma   (Italy)

Author keywords

Angiogenesis; CD105; Colon cancer; Metastasis risk; Prognosis

Indexed keywords

ENDOGLIN; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOLID TUMOR; ADENOCARCINOMA; CELL MOTION; COLORECTAL TUMOR; IMMUNOLOGY; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REGRESSION ANALYSIS; VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, CELL SURFACE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 33646828741     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20456     Document Type: Article

References (51)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Risau W: Mechanisms of angiogenesis. Nature 1997;386:671-674.
3. Weidner N, Folkman J, Pozza F, et al.: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
4. Weidner N, Semple JP, Welch WR, et al.: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
5. Srivastava A, Laidler P, Davies RP, et al.: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol 1988;133:419-423.
6. Chung YS, Maeda K, Sowa M: Prognostic value of angiogenesis in gastro-intestinal tumours. Eur J Cancer 1996;32A:2501-2505.
7. Abdalla SA, Behzad F, Bsharah S, et al.: Prognostic relevance of microvessel density in colorectal tumours. Oncol Rep 1999;6:839-842.
8. Saito H, Tsujitani S: Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma. Anticancer Res 2001;21:4365-4372.
9. Schimming R, Marme D: Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck 2002;24:151-156.
10. Brekken RA, Li C, Kumar S: Strategies for vascular targeting in tumors. Int J Cancer 2002;100:123-130.
11. Fonsatti E, Del Vecchio L, Altomonte M, et al.: Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001;188:1-7.
12. Sanchez-Elsner T, Botella LM, Velasco B, et al.: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43799-43808.
13. Quackenbush EJ, Cruz TF, Moscarello MA, et al.: Identification of three antigens in human brain associated with similar antigens on human leukaemic cells. Biochem J 1985;225:291-299.
14. Gougos A, Letarte M: Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988;141:1925-1933.
15. Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990;265:8361-8364.
16. Barbara NP, Wrana JL, Letarte M: Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999;274:584-594.
17. Bellon T, Corbi A, Lastres P, et al.: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993;23:2340-2345.
18. Miller DW, Graulich W, Karges B, et al.: Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81:568-572.
19. Bodey B, Bodey B, Jr., Siegel SE, et al.: Over-expression of endoglin (CD105): A marker of breast carcinoma-induced neovascularization. Anticancer Res 1998;18:3621-3628.
20. Kumar S, Ghellal A, Li C, et al.: Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856-861.
21. Kumar P, Wang JM, Bernabeu C: CD 105 and angiogenesis. J Pathol 1996;178:363-366.
22. Saad RS, Liu YL, Nathan G, et al.: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004;17:197-203.
23. Li C, Gardy R, Seon BK, et al.: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003;88:1424-1431.
24. Wikstrom P, Lissbrant IF, Stattin P, et al.: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268-275.
25. Dales JP, Garcia S, Bonnier P, et al.: CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 2003;119:374-380.
26. Greene FL, Page DL, Fleming ID, et al., editors. AJCC Cancer Staging Manual, 6th ed. New York: Springer; 2002.
27. Schor AM, Pendleton N, Pazouki S, et al.: Assessment of vascularity in histological sections: Effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998;30:849-856.
28. Vermeulen PB, Gasparini G, Fox SB, et al.: Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 2002;38:1564-1579.
29. Fleming T, Harrington D: Non-parametric estimation of the survival distribution in censored data. Comunication Stat: Theory Methods 1984;13:2469-2486.
30. Hsieh FY, Lavori PW: Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials 2000;21:552-560.
31. Verweij PJ, Van Houwelingen HC: Cross-validation in survival analysis. Stat Med 1993;12:2305-2314.
32. Hothorn T, Lausen B: On the exact distribution of maximally selected rank statistics. Comput Stat Data Analysis 2003;43:121-137.
33. Akaike H: A new look at the statistical model identification. IEEE Trans Automatic Control 1974;AC-19:716-723.
34. Kent JT, O'Quigley J: Measures of dependence for censored survival data. Biometrika 1988;75:525-534.
35. Machover D, Goldschmidt E, Chollet P, et al.: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and hish-dose folinic acid. NCI Monogr 1987;5:193-198.
36. Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-358.
37. Jacobs TW, Prioleau JE, Stillman IE, et al.: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88:1054-1059.
38. Vermeulen PB, Van den Eynden GG, Huget P, et al.: Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999;79:316-322.
39. Dales JP, Garcia S, Andrac L, et al.: Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: Correlation with long-term patient outcome. Int J Oncol 2004;24:1197-1204.
40. Arakawa A, Soh S, Chakraborty S, et al.: Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen. Prostate Cancer Prostatic Dis 1997;1:32-38.
41. Prall F, Gringmuth U, Nizze H, et al.: Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: Significant correlation of high microvessel densities with better survival. Histopathology 2003;42:482-491.
42. Dekel Y, Koren R, Kugel V, et al.: Significance of angiogenesis and microvascular invasion in renal cell carcinoma. Pathol Oncol Res 2002;8:129-132.
43. Akslen LA, Livolsi VA: Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol 2000;31:439-442.
44. Pignataro L, Carboni N, Midolo V, et al.: Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. Int J Cancer 2001;92:666-670.
45. Akagi K, Ikeda Y, Sumiyoshi Y, et al.: Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 2002;131:S109-S113.
46. Fonsatti E, Altomonte M, Arslan P, et al.: Endoglin (CD105): A target for anti-angiogenetic cancer therapy. Curr Drug Targets 2003;4:291-296.
47. Salvesen HB, Gulluoglu MG, Stefansson I, et al.: Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Apmis 2003;111:1011-1018.
48. Baluk P, Morikawa S, Haskell A, et al.: Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003;163:1801-1815.
49. Paku S, Paweletz N: First steps of tumor-related angiogenesis. Lab Invest 1991;65:334-346.
50. Verbel DA, Heller G, Kelly WK, et al.: Quantifying the amount of variation in survival explained by prostate-specific antigen. Clin Cancer Res 2002;8:2576-2579.
51. Charpin-Taranger C, Dales JP, Garcia S, et al.: [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers]. Bull Acad Natl Med 2003;187:1129-1145; discussion 1145-1126.